1. A two decade long study of disease progression of de novo and recurrent autoimmune hepatitis in the pediatric population
- Author
-
Nitika A. Gupta, Suresh Venkateswaran, Lori Hall, Carlos R. Abramowsky, Vasantha L. Kolachala, Scott Gillespie, Sirish Palle, and Timothy A. Hadley
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,030232 urology & nephrology ,Autoimmune hepatitis ,030230 surgery ,Plasma cell ,Liver transplantation ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,immune system diseases ,Recurrence ,Risk Factors ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,Child ,Retrospective Studies ,CD20 ,Transplantation ,medicine.diagnostic_test ,biology ,business.industry ,Graft Survival ,Histology ,medicine.disease ,Liver Transplantation ,Hepatitis, Autoimmune ,medicine.anatomical_structure ,Liver ,Liver biopsy ,Case-Control Studies ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,biology.protein ,Etiology ,Disease Progression ,Female ,business ,Biomarkers ,Pediatric population ,Follow-Up Studies - Abstract
Recurrent autoimmune hepatitis (rAIH) occurs in patients who undergo liver transplantation (LT) for AIH and de novo AIH (dAIH) is seen in patients who are transplanted for etiologies other than AIH. Whether these are distinct diseases with a similar phenotype remains understudied. The aim of this study was to identify clinical and immunologic factors affecting outcome in patients with dAIH and rAIH. A retrospective review of 387 LT patients from 1997 to 2014 was carried out, and they were followed until 2018. Patients with rAIH or dAIH were identified based on the pre-transplant diagnosis of AIH (or not) and characteristic histology. Liver biopsies were stained with H&E, B-cell marker CD20, and plasma cell marker CD138. Out of 387 patients, 31 were transplanted for AIH, and 8/31 developed rAIH. Of the remaining 356 patients, eight developed dAIH. Compared to the dAIH group, rAIH occurred in older patients, had an earlier onset in the allograft, and had higher IgG and serum ALT levels. It was most commonly seen in African American (AA) patients (87%). rAIH patients had significantly higher CD20 and CD138 positivity in liver biopsies. In addition, they had increased rejection episodes prior to the onset of recurrence, increased graft loss, and mortality. rAIH is a more aggressive disease, and has a preponderance of B cells and plasma cells in the liver tissue as compared to dAIH. The concurrent association with increased graft loss and patient mortality in rAIH warrants further investigations into B cell-targeted therapies.
- Published
- 2020